Paul M Hassoun, M.D.

Since 2002, Dr. Hassoun has been the director of the Johns Hopkins pulmonary hypertension (PH) program, a large clinical program with outpatient and inpatient practice dedicated to the diagnosis and treatment, in a multidisciplinary fashion, of all 5 disease groups from the World Classification of PH. Dr. Hassoun has led programmatic efforts to develop both clinical and basic research in PH. He was the PI of the Hopkins NIH/NHLBI Specialized Center of Clinically Oriented Research (SCCOR) in pulmonary vascular disease (1/2007-12/2014-NCE), with a focus on highly translational research to understand the complex pathobiology of scleroderma-associated pulmonary arterial hypertension (PAH) and was recently the co-PI of an R01 dedicated to uncovering the mechanisms of right ventricular dysfunction in PAH (08/2012-05/2017). He is currently the co-PI of the NIH/NHLBI/PAH-sponsored Johns Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics (PVDOMICS) program, a project dedicated to establishing a clinical center for the diagnosis and treatment of PH offering a unique expertise of multidisciplinary and highly integrated team of experts with the capacity to use clinical, imaging, and molecular tools to redefine PH phenotypes. Under his directorship, the Johns Hopkins PH program has become a premier center for the comprehensive and multidisciplinary evaluation and treatment of patients with PH. Using state-of-the art-imaging techniques, epidemiological and genetic studies, and basic research, the program's team has advanced the understanding of unique aspects of right ventricular myocardial dysfunction in PAH. Dr. Hassoun has also led a successful research program in the field of pulmonary vascular and endothelial cell biology and has maintained continuous NIH funding since 1989.